(0.09%) 5 308.13 points
(-0.49%) 39 807 points
(0.65%) 16 795 points
(-0.23%) $79.62
(-0.22%) $2.75
(-0.60%) $2 423.90
(-2.16%) $31.73
(-1.40%) $1 048.80
(0.09%) $0.921
(0.30%) $10.73
(0.06%) $0.787
(0.03%) $90.70
10.52% $ 0.308
Live Chart Being Loaded With Signals
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China...
Stats | |
---|---|
Dzisiejszy wolumen | 24 323.00 |
Średni wolumen | 190 072 |
Kapitalizacja rynkowa | 3.42M |
EPS | $0 ( 2024-04-02 ) |
Następna data zysków | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.190 |
ATR14 | $0.00900 (2.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2021-05-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2022-05-01 | Tauzin W J | Buy | 8 000 | Stock Option right to buy) |
2022-11-01 | Tauzin W J | Buy | 8 000 | Stock Option (right to buy) |
2022-01-01 | Tauzin W J | Buy | 4 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
99.83 |
Last 100 transactions |
Buy: 44 704 561 | Sell: 8 187 803 |
Wolumen Korelacja
Avalon GloboCare Corp. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Avalon GloboCare Corp. Korelacja - Waluta/Towar
Avalon GloboCare Corp. Finanse
Annual | 2023 |
Przychody: | $1.26M |
Zysk brutto: | $202 789 (16.15 %) |
EPS: | $-1.590 |
FY | 2023 |
Przychody: | $1.26M |
Zysk brutto: | $202 789 (16.15 %) |
EPS: | $-1.590 |
FY | 2022 |
Przychody: | $1.20M |
Zysk brutto: | $272 728 (22.69 %) |
EPS: | $-1.360 |
FY | 2021 |
Przychody: | $1.39M |
Zysk brutto: | $414 518 (29.80 %) |
EPS: | $-1.100 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej